Home › Business & Finance › Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials
Business & Finance

Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials

Key Points

Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials Bambusa Therapeutics Inc. filed for a initial public offering to help fund trials of its drugs to treat eczema and other inflammation disorders. The Boston-based company is working on long-acting bispecific antibodies to treat unmet needs in the more than $150 billion-a-year global immunology and inflammation market, encompassing skin, respiratory, gastroenterology and autoimmune diseases, according to a filing Friday with the US...

Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials Bambusa Therapeutics Inc. filed for a initial public offering to help fund trials of its drugs to treat eczema and other inflammation disorders. The Boston-based company is working on long-acting bispecific antibodies to treat unmet needs in the more than $150 billion-a-year global immunology and inflammation market, encompassing skin, respiratory, gastroenterology and autoimmune diseases, according to a filing Friday with the US Securities and Exchange Commission.
IPO (ORG) Boston (LOCATION) the US Securities and Exchange Commission (ORG)
Originally published by Bloomberg Markets Read original →